These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 8104682)

  • 41. Schedule-dependent synergism of taxol or taxotere with edatrexate against human breast cancer cells in vitro.
    Chou TC; Otter GM; Sirotnak FM
    Cancer Chemother Pharmacol; 1996; 37(3):222-8. PubMed ID: 8529281
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combination paclitaxel (Taxol) and doxorubicin therapy for metastatic breast cancer.
    O'Shaughnessy JA; Fisherman JS; Cowan KH
    Semin Oncol; 1994 Oct; 21(5 Suppl 8):19-23. PubMed ID: 7939757
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Schedule-dependent interactions between paclitaxel and etoposide in human carcinoma cell lines in vitro.
    Kano Y; Akutsu M; Suzuki K; Mori K; Yazawa Y; Tsunoda S
    Cancer Chemother Pharmacol; 1999; 44(5):381-8. PubMed ID: 10501911
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into the clinic.
    Vanhoefer U; Schleucher N; Klaassen U; Seeber S; Harstrick A
    Semin Oncol; 2000 Feb; 27(1 Suppl 1):8-13. PubMed ID: 10697038
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Doxazosin: a new cytotoxic agent for prostate cancer?
    Cal C; Uslu R; Gunaydin G; Ozyurt C; Omay SB
    BJU Int; 2000 Apr; 85(6):672-5. PubMed ID: 10759663
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vitro studies of Taxol as a radiation sensitizer in human tumor cells.
    Liebmann J; Cook JA; Fisher J; Teague D; Mitchell JB
    J Natl Cancer Inst; 1994 Mar; 86(6):441-6. PubMed ID: 7907149
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
    Menendez JA; Vellon L; Colomer R; Lupu R
    Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combination paclitaxel and vinorelbine therapy: in vitro cytotoxic interactions and dose-escalation study in breast cancer patients previously exposed to anthracyclines.
    Culine S; Roch I; Pinguet F; Romieu G; Bressolle F
    Int J Oncol; 1999 May; 14(5):999-1006. PubMed ID: 10200354
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Taxol induced apoptosis regulates amino acid transport in breast cancer cells.
    Wu Y; Shen D; Chen Z; Clayton S; Vadgama JV
    Apoptosis; 2007 Mar; 12(3):593-612. PubMed ID: 17195090
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A sequence-dependent paclitaxel/etoposide phase II trial in patients with non-small cell lung cancer.
    Rosell R; Felip E; Massuti B; González-Larriba JL; Benito D; López-Cabrerizo MP; Salamanca O; Camps C; Puerto-Pica J
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-56-S12-60. PubMed ID: 9331123
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cell line and schedule-dependent cytotoxicity of paclitaxel (Taxol): role of the solvent Cremophor EL/ethanol.
    Cordes N; Plasswilm L
    Anticancer Res; 1998; 18(3A):1851-7. PubMed ID: 9673415
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Schedule-dependent synergism and antagonism between paclitaxel and methotrexate in human carcinoma cell lines.
    Kano Y; Akutsu M; Tsunoda S; Furuta M; Yazawa Y; Ando J
    Oncol Res; 1998; 10(7):347-54. PubMed ID: 10063968
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A new superinvasive in vitro phenotype induced by selection of human breast carcinoma cells with the chemotherapeutic drugs paclitaxel and doxorubicin.
    Glynn SA; Gammell P; Heenan M; O'Connor R; Liang Y; Keenan J; Clynes M
    Br J Cancer; 2004 Nov; 91(10):1800-7. PubMed ID: 15505620
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.
    Drevs J; Fakler J; Eisele S; Medinger M; Bing G; Esser N; Marmé D; Unger C
    Anticancer Res; 2004; 24(3a):1759-63. PubMed ID: 15274352
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Experimental study on the combined treatment of UFT with etoposide against mouse Lewis lung carcinoma].
    Takechi T; Nakano K; Uchida J; Takeda S
    Gan To Kagaku Ryoho; 1993 Feb; 20(2):235-40. PubMed ID: 8434961
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage.
    Jensen PB; Sørensen BS; Demant EJ; Sehested M; Jensen PS; Vindeløv L; Hansen HH
    Cancer Res; 1990 Jun; 50(11):3311-6. PubMed ID: 2159380
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy.
    Hainsworth JD; Greco FA
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):45-9. PubMed ID: 8643970
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Schedule-dependent interaction of paclitaxel (Taxol) and irradiation in vitro.
    Plasswilm L; Cordes N; Sauer R
    Radiat Oncol Investig; 1998; 6(1):10-7. PubMed ID: 9503485
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Potential antagonism of tubulin-binding anticancer agents in combination therapies.
    Taraboletti G; Micheletti G; Dossi R; Borsotti P; Martinelli M; Fiordaliso F; Ryan AJ; Giavazzi R
    Clin Cancer Res; 2005 Apr; 11(7):2720-6. PubMed ID: 15814654
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Paclitaxel-based combination chemotherapy for breast cancer.
    Hortobagyi GN
    Oncology (Williston Park); 1997 Mar; 11(3 Suppl 2):29-37. PubMed ID: 9110340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.